Literature DB >> 1169237

Studies on the primary structure of bovine high-molecular-weight kininogen. Amino acid sequence of a fragment ("histidine-rich peptide") released by plasma kallikrein.

Y N Han, M Komiya, S Iwanaga, T Suzuki.   

Abstract

An unknown peptide fragment, which was released from bovine high-molecular-weight kininogen by bovine plasma kallikrein [EC 3.4.21.8], was isolated and its chemical structure was established. The fragment consisted of 41 amino acids with serine and arginine at the NH2- and COOH-termini, respectively. The molecular weight was calculated to be 4,584. It was very basic and contained eleven residues each of histidine and glycine and seven residues of lysine. Thus, the total number of these three amino acids accounted for about 70 percent of the total residues constituting the fragment. The amino acid sequence of the fragment, designated tentatively as "His-rich peptide," was studied by Edman degradation and standard enzymatic and chemical techniques. These data made it possible to deduce the following sequence: H-Ser-His-Gly-Leu-Gly-His-Gly-His-Gln-Lys-Gln-His-Gly-Leu-Gly-His-Gly-His-Lys-His-Gly-His-Gly-His-Gly-Lys-His-Lys-Asn-Lys-Gly-Lys-Asn-Asn-Gly-Lys-His-Tyr-Asp-Trp-Arg-OH. The fragment had an extremely interesting feature in that repeating sequences occur along the peptide chain. The repeats were of the type His-Gly-X or Gly-His-X and this sequence appeared six or seven times up to 26 residues from the N-terminal end. Moreover, three tetrapeptide sequences of Gly-His-Gly-His and two heptapeptide sequence consisting of His-Gly-Leu-Gly-His-Gly-His were found in the N-terminal portion. It should be noted that plasma kallikrein liberates such a histidine-rich peptide from the kininogen in addition to a physiologically active peptide, bradykinin. The location of the "His-rich peptide" fragment in the percursor protein is also discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1169237

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  8 in total

1.  Flaujeac factor deficiency. Reconstitution with highly purified bovine high molecular weight-kininogen and delineation of a new permeability-enhancing peptide released by plasma kallikrein from bovine high molecular weight-kininogen.

Authors:  R T Matheson; D R Miller; M J Lacombe; Y N Han; S Iwanaga; H Kato; K D wuepper
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

2.  A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein.

Authors:  H Lilja
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

3.  Purification of enzymes of the kallikrein gene family (rK8 and rK9) from the rat prostate.

Authors:  H Schøyen; I Wassdal; K Toft; M Almendingen; T Berg
Journal:  Biochem J       Date:  1994-08-15       Impact factor: 3.857

4.  Primary structures of bovine liver low molecular weight kininogen precursors and their two mRNAs.

Authors:  H Nawa; N Kitamura; T Hirose; M Asai; S Inayama; S Nakanishi
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

5.  A putative transmembrane protein with histidine-rich charge clusters encoded in the H-2K/tw5 region of mice.

Authors:  B St-Jacques; T H Han; A MacMurray; H S Shin
Journal:  Mol Cell Biol       Date:  1990-01       Impact factor: 4.272

Review 6.  On the Functional Overlap between Complement and Anti-Microbial Peptides.

Authors:  Jana Zimmer; James Hobkirk; Fatima Mohamed; Michael J Browning; Cordula M Stover
Journal:  Front Immunol       Date:  2015-01-19       Impact factor: 7.561

7.  Characterization of human high molecular weight kininogen. Procoagulant activity associated with the light chain of kinin-free high molecular weight kininogen.

Authors:  R E Thompson; R Mandle; A P Kaplan
Journal:  J Exp Med       Date:  1978-02-01       Impact factor: 14.307

8.  Relation between structure and correcting activity of bovine high molecular weight kininogen upon the clotting time of Fitzgerald-trait plasma.

Authors:  A G Scicli; R Waldmann; J A Guimaraes; G Scicli; O A Carretero; H Kato; Y N Han; S Iwanaga
Journal:  J Exp Med       Date:  1979-04-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.